Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03028935
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Phase 1
Completed
- Conditions
- Locally Advanced AngiosarcomaLocally Advanced LeiomyosarcomaLocally Advanced Malignant Peripheral Nerve Sheath TumorMetastatic Epithelioid SarcomaMetastatic FibrosarcomaMetastatic Undifferentiated Pleomorphic SarcomaUnresectable LeiomyosarcomaLocally Advanced MyxofibrosarcomaMetastatic AngiosarcomaMyxofibrosarcoma
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT03009201
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Assessing Community Cancer Care After Insurance ExpanSionS
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1939783
- Registration Number
- NCT02936609
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT02890979
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT02869412
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT02857218
Pre-Prostatectomy Celecoxib or Placebo
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT02840162
- Locations
- 🇺🇸
Portland VA Medical Center, Portland, Oregon, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: DasatinibDrug: IdarubicinDrug: IdelalisibDrug: DexamethasoneDevice: In Vitro Kinase Inhibitor AssayDrug: Doxorubicin HydrochlorideDrug: Ponatinib HydrochlorideDrug: Ruxolitinib PhosphateDrug: Sorafenib TosylateDrug: Leucovorin CalciumDrug: Sunitinib MalateDrug: MethotrexateDrug: Methylprednisolone Sodium SuccinateBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02779283
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT02736617
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02522715
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Portland VA Medical Center, Portland, Oregon, United States
© Copyright 2024. All Rights Reserved by MedPath